Press "Enter" to skip to content

AVEO Pharmaceuticals reports net lack of $14.

General and administrative expenditure was $2.8 million for the 1st quarter of 2010 compared with $2.6 million for the first quarter of 2009. By March 31, 2010, AVEO had cash, cash equivalents and marketable securities of $96.1 million weighed against $51.on December 31 3 million, 2009. On March 17, 2010, the company completed its initial public offering of 9 million shares of common stock. On March 31, 2010, the underwriters for the initial public offering exercised their substitute for purchase an additional 968,000 shares of common stock to cover over-allotments.This has great potential for developing therapies for cancer, where keeping the enzyme in its 'on' placement will promote tumor cell death. We also wish to accomplish the contrary in neurodegenerative diseases, in which we need treatments that maintain neurons alive. Related StoriesCrucial change in single DNA base predisposes children to intense form of cancerUnderstanding how schizophrenia impacts workings of the brainSausages With Antioxidants From Berries TO AVOID CancerResearchers typically make use of a technique called X-ray crystallography to look for the 3D structure of proteins. But occasionally they have to make assumptions to be able to fit the info together as greatest they can.